Zobrazeno 1 - 10
of 16
pro vyhledávání: '"R. M. Reilly"'
Autor:
Eszter Pakai, Andrej A. Romanovsky, A. Gomtsyan, Narender R. Gavva, Dawn Zhu, Joshua J. Corrigan, R. M. Reilly, H. A. McDonald, Sonya G. Lehto, P. R. Kym, Erika Pintér, András Garami
Publikováno v:
Acta Physiologica. 223:e13038
Aim Thermoregulatory side effects hinder the development of transient receptor potential vanilloid-1 (TRPV1) antagonists as new painkillers. While many antagonists cause hyperthermia, a well-studied effect, some cause hypothermia. The mechanisms of t
Autor:
K McLarty, R M Reilly
Publikováno v:
Clinical Pharmacology & Therapeutics. 81:420-424
Cancer is not a single disease, but rather a collection of diseases in individuals that are well recognized to vary significantly in their molecular biology, clinical presentation, and outcome. 1 In this context, there can be no better argument for p
Publikováno v:
Lymphology. 41(4)
The study examined the impact of size on lymphatic particle distribution through intrapleural (ipl.) administration. Aminopolystyrene of three sizes, 0.29 microm, 2.18 microm, and 11.2 microm were radiolabeled with 111Indium and their biodistribution
Autor:
Y, Luo, S K, Rockow-Magnone, M K, Joseph, J, Bradner, C C, Butler, S K, Tahir, E K, Han, S C, Ng, J M, Severin, E J, Gubbins, R M, Reilly, A, Rueter, R L, Simmer, T F, Holzman, V L, Giranda
Publikováno v:
Anticancer research. 21(1A)
Chkl is a checkpoint gene that is activated after DNA damage. It phosphorylates and inactivates Cdc25C at the late G2 phase. The inactivation of Cdc25C and consequently, the inactivation of Cdc2, are required for the G2 arrest induced by DNA damage.W
Autor:
R M, Reilly, R, Kiarash, J, Sandhu, Y W, Lee, R G, Cameron, A, Hendler, K, Vallis, J, Gariépy
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 41(5)
Our objective was to compare 111In-labeled human epidermal growth factor (hEGF), a 53-amino acid peptide with anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb) 528 (IgG2a) for imaging EGFR-positive breast cancer.hEGF and MAb 528
Autor:
R M, Reilly, J, Gariépy
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 39(6)
The overexpression of cell surface receptors on cancer cells is a potential target for the design of receptor-binding radiopharmaceuticals for tumor imaging. The sensitivity of these agents depends on the interaction in vivo of factors such as the le
Autor:
S, Gallinger, R M, Reilly, J C, Kirsh, R D, Odze, B J, Schmocker, K, Hay, J, Polihronis, M T, Damani, B, Shpitz, H S, Stern
Publikováno v:
Cancer research. 53(2)
Radiolabeled first-generation anti-tumor-associated glycoprotein-72 (TAG-72) monoclonal antibody (MAb), B72.3, has proven useful in detecting primary and secondary colorectal carcinoma. It has been anticipated that the development of second-generatio
Autor:
S, Gallinger, M Z, Papa, R M, Reilly, J, Xiang, J C, Kirsh, J B, Mullen, H S, Stern, N, Hozumi, J C, Roder
Publikováno v:
Molecular biotherapy. 3(4)
We have recently chimerized the heavy chain of the pan-carcinoma monoclonal antibody (mAb) B72.3. Studies were undertaken to compare the IgG1 chimeric antibody, B72.3-1-3 with native murine B72.3 (nB72.3). Using fluorescence-activated cell sorting an
Autor:
R M, Reilly
Publikováno v:
Clinical pharmacy. 10(5)
The critical issues in radioimmunotherapy are highlighted, and novel ways of improving the therapeutic indexes of radioimmunotherapeutic agents are outlined. The use of radioactively labeled monoclonal antibodies to treat malignant tumors has been in
Publikováno v:
The Journal of Immunology. 133:471-475
To learn about the V lambda gene segments that are expressed in lambda 3 light chains, the most recently identified lambda-chain subtype in inbred mice, we determined partial amino acid sequences of the V regions of two of these chains, L5-8 and Lc49